Arch Therapeutics, Inc. (ARTH)
USD 0.16
(-10.93%)
USD 0.16
(-10.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.98 Million USD | -63.31% |
| 2022 | -4.27 Million USD | 34.91% |
| 2021 | -6.56 Million USD | -63.74% |
| 2020 | -4.01 Million USD | -47.32% |
| 2019 | -2.72 Million USD | 43.43% |
| 2018 | -4.81 Million USD | 38.19% |
| 2017 | -7.78 Million USD | -29.98% |
| 2016 | -5.99 Million USD | -103.3% |
| 2015 | -2.94 Million USD | 63.8% |
| 2014 | -8.14 Million USD | -339.25% |
| 2013 | -1.85 Million USD | -4963.48% |
| 2012 | -36.61 Thousand USD | -626.84% |
| 2011 | -5037.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -2.68 Million USD | -9.13% |
| 2024 Q2 | -1.46 Million USD | 45.22% |
| 2024 Q3 | -5.65 Million USD | -284.9% |
| 2023 Q1 | -2.32 Million USD | 0.5% |
| 2023 Q2 | -1.01 Million USD | 56.35% |
| 2023 FY | -6.98 Million USD | -63.31% |
| 2023 Q3 | -1.82 Million USD | -79.68% |
| 2023 Q4 | -2.45 Million USD | -34.78% |
| 2022 Q2 | -790.31 Thousand USD | 49.02% |
| 2022 FY | -4.27 Million USD | 34.91% |
| 2022 Q4 | -2.33 Million USD | -114.95% |
| 2022 Q1 | -1.55 Million USD | 12.18% |
| 2022 Q3 | -1.08 Million USD | -37.5% |
| 2021 Q1 | -1.15 Million USD | 17.29% |
| 2021 Q4 | -1.76 Million USD | -15.38% |
| 2021 FY | -6.56 Million USD | -63.74% |
| 2021 Q2 | -1.79 Million USD | -55.21% |
| 2021 Q3 | -1.52 Million USD | 14.59% |
| 2020 Q3 | -904.36 Thousand USD | -23.57% |
| 2020 Q1 | -1.65 Million USD | -100.42% |
| 2020 Q2 | -731.88 Thousand USD | 55.9% |
| 2020 Q4 | -1.39 Million USD | -54.29% |
| 2020 FY | -4.01 Million USD | -47.32% |
| 2019 Q3 | -1.28 Million USD | -858.5% |
| 2019 Q4 | -828.14 Thousand USD | 35.76% |
| 2019 FY | -2.72 Million USD | 43.43% |
| 2019 Q1 | -2.6 Million USD | -81.18% |
| 2019 Q2 | 169.96 Thousand USD | 106.54% |
| 2018 Q2 | -1.55 Million USD | -499.65% |
| 2018 FY | -4.81 Million USD | 38.19% |
| 2018 Q4 | -1.43 Million USD | 35.14% |
| 2018 Q3 | -2.21 Million USD | -42.26% |
| 2018 Q1 | 389.17 Thousand USD | 114.19% |
| 2017 Q4 | -2.74 Million USD | -54.42% |
| 2017 FY | -7.78 Million USD | -29.98% |
| 2017 Q1 | -1.4 Million USD | 22.86% |
| 2017 Q2 | -1.86 Million USD | -33.39% |
| 2017 Q3 | -1.77 Million USD | 5.01% |
| 2016 Q1 | -1.15 Million USD | -5.39% |
| 2016 FY | -5.99 Million USD | -103.3% |
| 2016 Q4 | -1.81 Million USD | -2.89% |
| 2016 Q3 | -1.76 Million USD | -40.92% |
| 2016 Q2 | -1.25 Million USD | -8.33% |
| 2015 Q2 | -833.96 Thousand USD | -319.96% |
| 2015 FY | -2.94 Million USD | 63.8% |
| 2015 Q1 | 379.14 Thousand USD | -40.29% |
| 2015 Q4 | -1.09 Million USD | 21.34% |
| 2015 Q3 | -1.39 Million USD | -67.3% |
| 2014 FY | -8.14 Million USD | -339.25% |
| 2014 Q4 | 635.01 Thousand USD | 54.6% |
| 2014 Q3 | 410.75 Thousand USD | 104.9% |
| 2014 Q2 | -8.38 Million USD | -936.58% |
| 2014 Q1 | -808.44 Thousand USD | 15.92% |
| 2013 Q3 | -514.36 Thousand USD | -11214.58% |
| 2013 Q4 | -961.53 Thousand USD | -86.94% |
| 2013 FY | -1.85 Million USD | -4963.48% |
| 2013 Q2 | -4546.00 USD | -259.37% |
| 2013 Q1 | -1265.00 USD | 93.89% |
| 2012 Q2 | -9108.00 USD | -949.31% |
| 2012 Q4 | -20.71 Thousand USD | -250.14% |
| 2012 FY | -36.61 Thousand USD | -626.84% |
| 2012 Q1 | -868.00 USD | 82.57% |
| 2012 Q3 | -5917.00 USD | 35.04% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | -5037.00 USD | 0.0% |
| 2011 Q3 | -19.00 USD | 0.0% |
| 2011 Q4 | -4981.00 USD | -26115.79% |
| 2011 Q2 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -422.89% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 113.18% |
| Nascent Biotech, Inc. | -2.08 Million USD | -234.478% |
| Rebus Holdings, Inc. | -1.02 Million USD | -584.592% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 110.721% |
| Qrons Inc. | -789.34 Thousand USD | -784.635% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1004.168% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 88.845% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1580.671% |
| Skye Bioscience, Inc. | -37.64 Million USD | 81.451% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 90.685% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -6.185% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2454.054% |
| SQZ Biotechnologies Company | -79.46 Million USD | 91.213% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -141.421% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -283.561% |
| Mesoblast Limited | -87.95 Million USD | 92.061% |
| Marizyme, Inc. | -65.34 Million USD | 89.314% |
| Genus plc | 7.9 Million USD | 188.39% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 35.889% |
| Pharming Group N.V. | -10.54 Million USD | 33.799% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -221.817% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -88.205% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 21.044% |
| ContraFect Corporation | -65.15 Million USD | 89.282% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -42.913% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -304.227% |
| IMV Inc. | -36.48 Million USD | 80.861% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 13.361% |
| MultiCell Technologies, Inc. | -380.07 USD | -1837149.98% |
| ONE Bio Corp. | 8.67 Million USD | 180.479% |
| Accustem Sciences Inc. | -3.74 Million USD | -86.387% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 86.491% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -451.073% |
| Q BioMed Inc. | -2.05 Million USD | -240.279% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -87.057% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -193.289% |
| Biomind Labs Inc. | -1.21 Million USD | -475.041% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 88.308% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -125.124% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 11.644% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -258.232% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -46526.843% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 56.004% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -20.037% |
| GB Sciences, Inc. | -1.36 Million USD | -412.811% |
| Alpha Cognition Inc. | -13.77 Million USD | 49.299% |
| HST Global, Inc. | -146.21 Thousand USD | -4675.895% |
| CSL Limited | 2.64 Billion USD | 100.264% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -297.934% |
| Halberd Corporation | -79.67 Thousand USD | -8664.039% |
| Enzolytics Inc. | -2.17 Million USD | -220.78% |
| Agentix Corp. | -1.37 Million USD | -408.134% |
| Resverlogix Corp. | -3.61 Million USD | -93.43% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -120.179% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.633% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 7225.343% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 200.841% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -75.758% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -130.751% |
| AVAX Technologies, Inc. | -6.41 Million USD | -8.875% |
| Zenith Capital Corp. | -10.59 Million USD | 34.099% |
| Genscript Biotech Corporation | -95.47 Million USD | 92.686% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -29944.041% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -68.426% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -11453.219% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -248.251% |
| Kadimastem Ltd | -3.3 Million USD | -111.128% |
| Helix BioMedix, Inc. | -1.05 Million USD | -561.218% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -82.845% |
| BioStem Technologies, Inc. | -8.48 Million USD | 17.684% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1482.086% |
| LadRx Corporation | 400.44 Thousand USD | 1843.778% |
| Cell Source, Inc. | -5.32 Million USD | -31.226% |
| Regen BioPharma, Inc. | 1.02 Million USD | 782.245% |
| Regen BioPharma, Inc. | 1.02 Million USD | 782.245% |
| NovAccess Global Inc. | -4.76 Million USD | -46.416% |
| Affymax, Inc. | -14.42 Million USD | 51.589% |
| Itoco Inc. | -1.86 Million USD | -273.614% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -57.181% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -318.384% |
| Mobile Lads Corp. | -2.26 Million USD | -208.526% |
| CytoDyn Inc. | -49.84 Million USD | 85.99% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -8735.342% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2960.942% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -641.649% |
| SYBLEU INC | -180.3 Thousand USD | -3772.813% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -332.98% |
| International Stem Cell Corporation | -131 Thousand USD | -5230.409% |
| Bioxytran, Inc. | -4.28 Million USD | -63.15% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -12766.369% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -175.974% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 85.474% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -230.314% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -794.218% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -120.418% |
| Neutra Corp. | -233.46 Thousand USD | -2890.956% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 65.587% |
| PureTech Health plc | -65.69 Million USD | 89.371% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 67.165% |
| IXICO plc | -1.17 Million USD | -492.77% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 29.658% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 87.777% |
| CSL Limited | 2.64 Billion USD | 100.264% |
| Cellectis S.A. | -103.17 Million USD | 93.232% |